Literature DB >> 8892014

In vivo disposal of phenylalanine in phenylketonuria: a study of two siblings.

E Treacy1, J J Pitt, K Seller, G N Thompson, S Ramus, R G Cotton.   

Abstract

Mutation at the phenylalanine hydroxylase (PAH) locus is a cause of hyperphenylalaninaemia. Genotype-phenotype correlation relative to the predicted PAH activity may differ at the metabolite level and at the IQ level in untreated phenylketonuria. Discordant metabolic phenotypes have been noted in siblings; influences on transport and metabolism of phenylalanine determining homeostasis may account for differing metabolic phenotypes. We report two siblings of different sex and identical genotype at the PAH locus who demonstrate a difference in phenylalanine disposal. A stable isotope infusion of [2H5]phenylalanine was used to measure protein turnover, phenylalanine hydroxylation and excretion of phenylalanine transamination metabolites. The siblings were observed to have identical hydroxylation rates under the experimental conditions of the study while manifesting differences in renal excretion rates of phenylalanine transamination metabolites and protein accretion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892014     DOI: 10.1007/bf01799832

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  29 in total

1.  A synopsis of the unconjugated acidic transamination metabolites of phenylalanine in phenylketonuria.

Authors:  U Langenbeck; A Behbehani; A Mench-Hoinowski
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

2.  Rapid measurement of whole body and forearm protein turnover using a [2H5]phenylalanine model.

Authors:  G N Thompson; P J Pacy; H Merritt; G C Ford; M A Read; K N Cheng; D Halliday
Journal:  Am J Physiol       Date:  1989-05

3.  Different phenotypic manifestations associated with identical phenylketonuria genotypes in two Spanish families.

Authors:  B Pérez; L R Desviat; M J García; M Ugarte
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

4.  Muscle protein synthesis measured by stable isotope techniques in man: the effects of feeding and fasting.

Authors:  M J Rennie; R H Edwards; D Halliday; D E Matthews; S L Wolman; D J Millward
Journal:  Clin Sci (Lond)       Date:  1982-12       Impact factor: 6.124

5.  Molecular basis of phenotypic heterogeneity in phenylketonuria.

Authors:  Y Okano; R C Eisensmith; F Güttler; U Lichter-Konecki; D S Konecki; F K Trefz; M Dasovich; T Wang; K Henriksen; H Lou
Journal:  N Engl J Med       Date:  1991-05-02       Impact factor: 91.245

6.  Ligand effects on the phosphorylation state of hepatic phenylalanine hydroxylase.

Authors:  R S Phillips; S Kaufman
Journal:  J Biol Chem       Date:  1984-02-25       Impact factor: 5.157

Review 7.  Clinical application of genotypic diagnosis for phenylketonuria: theoretical considerations.

Authors:  F D Ledley
Journal:  Eur J Pediatr       Date:  1991-09       Impact factor: 3.183

8.  Protein intake affects phenylalanine requirements and growth of infants with phenylketonuria.

Authors:  P B Acosta; S Yannicelli
Journal:  Acta Paediatr Suppl       Date:  1994-12

9.  Characterization of phenylalanine hydroxylase alleles in untreated phenylketonuria patients from Victoria, Australia: origin of alleles and haplotypes.

Authors:  S J Ramus; E P Treacy; R G Cotton
Journal:  Am J Hum Genet       Date:  1995-05       Impact factor: 11.025

10.  Permanent chemical phenylketonuria and a normal phenylalanine tolerance in two sisters with a normal mental development.

Authors:  S K Wadman; D Ketting; P K De Bree; C Van der Heiden; M T Grimberg; H Kruijswijk
Journal:  Clin Chim Acta       Date:  1975-12-01       Impact factor: 3.786

View more
  11 in total

1.  Development of Metabolic Phenotype in Phenylketonuria: Evaluation of the Blaskovics Protein Loading Test at 5 Years of Age.

Authors:  P Burgard; E Mönch; J Zschocke; U Wendel; U Langenbeck
Journal:  JIMD Rep       Date:  2015-12-19

2.  Modelling the phenylalanine blood level response during treatment of phenylketonuria.

Authors:  U Langenbeck; J Zschocke; U Wendel; V Hönig
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

3.  A model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients.

Authors:  S Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

4.  Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations.

Authors:  E Kayaalp; E Treacy; P J Waters; S Byck; P Nowacki; C R Scriver
Journal:  Am J Hum Genet       Date:  1997-12       Impact factor: 11.025

Review 5.  What we know that could influence future treatment of phenylketonuria.

Authors:  C N Sarkissian; A Gámez; C R Scriver
Journal:  J Inherit Metab Dis       Date:  2008-08-03       Impact factor: 4.982

6.  Metabolic phenotypes of phenylketonuria. Kinetic and molecular evaluation of the Blaskovics protein loading test.

Authors:  U Langenbeck; P Burgard; U Wendel; M Lindner; J Zschocke
Journal:  J Inherit Metab Dis       Date:  2009-07-16       Impact factor: 4.982

7.  Utility of phenylalanine hydroxylase genotype for tetrahydrobiopterin responsiveness classification in patients with phenylketonuria.

Authors:  Meghan E Quirk; Steven F Dobrowolski; Benjamin E Nelson; Bradford Coffee; Rani H Singh
Journal:  Mol Genet Metab       Date:  2012-07-20       Impact factor: 4.797

8.  Discordant PKU phenotype in one family due to disparate genotypes and a novel mutation.

Authors:  J J Johnston; U Lichter-Konecki; E Wilson; B R Cobb; B M Evans; R E Schnur; L-J C Wong
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

9.  An ongoing debate over phenylalanine hydroxylase deficiency in phenylketonuria.

Authors:  C R Scriver
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

10.  Phenylketonuria. The in vivo hydroxylation rate of phenylalanine into tyrosine is decreased.

Authors:  F J van Spronsen; D J Reijngoud; G P Smit; G T Nagel; F Stellaard; R Berger; H S Heymans
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.